Lars Ny

List of Publications by Year in descending order

93 papers	4,042 citations	136950 32 h-index	123424 61 g-index
99 all docs	99 docs citations	99 times ranked	5362 citing authors

#	Article	IF	Citations
1	Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma. Melanoma Research, 2022, 32, 241-248.	1.2	9
2	Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary. European Journal of Surgical Oncology, 2022, 48, 320-325.	1.0	18
3	PDâ€1 inhibitor therapy of basal cell carcinoma with pulmonary metastasis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 70-73.	2.4	3
4	Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors. Cancers, 2022, 14, 702.	3.7	3
5	The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases â€“ A multicenter cohort study. European Journal of Cancer, 2022, 169, 210-222.	2.8	12
6	Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial. Acta OncolÃ³gica, 2022, 61, 869-873.	1.8	1
7	Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage Iâ€“II Melanoma Patients at Risk of Disease Relapse. Cancers, 2022, 14, 2854.	3.7	9
8	The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases: A multicenter cohort study.. Journal of Clinical Oncology, 2022, 40, 9569-9569.	1.6	0
9	Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases, first results from a phase III randomized controlled multicenter trial (the SCANDIUM trial).. Journal of Clinical Oncology, 2022, 40, LBA9509-LBA9509.	1.6	6
10	Immune Checkpoint Inhibitor-Induced Polymyositis and Myasthenia Gravis with Fatal Outcome. Case Reports in Oncology, 2021, 13, 1252-1257.	0.7	8
11	Surgery of metastatic melanoma after systemic therapy â€“ the SUMMIST trial: study protocol for a randomized controlled trial. Acta OncolÃ³gica, 2021, 60, 52-55.	1.8	5
12	The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. Melanoma Research, 2021, 31, 181-185.	1.2	14
13	Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.. Journal of Clinical Oncology, 2021, 39, 9504-9504.	1.6	23
14	Plasma thymidine kinase activity (TKa) as a novel prognostic biomarker in metastatic melanoma.. Journal of Clinical Oncology, 2021, 39, 9556-9556.	1.6	0
15	Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis. , 2021, 9, e002732.		12
16	The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. Nature Communications, 2021, 12, 5155.	12.8	85
17	Intussusceptive Angiogenesis in Human Metastatic Malignant Melanoma. American Journal of Pathology, 2021, 191, 2023-2038.	3.8	13
18	Clinical outcomes in cancer patients with COVID-19 in Sweden. Acta OncolÃ³gica, 2021, 60, 1572-1579.	1.8	3

#	Article	IF	Citations
19	Reply to Comment on Katsarelias, D., et al. â€œThe Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanomaâ€”A Nation-Wide Swedish Population-Based Retrospective Register Study.â€• Cancers 2020, 12, 3228. Cancers, 2021, 13, 92.	3.7	1
20	Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma. Journal of Clinical Oncology, 2020, 38, 3937-3946.	1.6	119
21	The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanomaâ€”A Nation-Wide Swedish Population-Based Retrospective Register Study. Cancers, 2020, 12, 3228.	3.7	9
22	Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection. Case Reports in Oncology, 2020, 13, 478-484.	0.7	15
23	Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models. Annals of Oncology, 2020, 31, 266-273.	1.2	26
24	Radiation of the urinary bladder attenuates the development of lipopolysaccharide-induced cystitis. International Immunopharmacology, 2020, 83, 106334.	3.8	3
25	Molecular profiling of driver events in metastatic uveal melanoma. Nature Communications, 2020, 11, 1894.	12.8	108
26	BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis. Acta OncolÃ³gica, 2020, 59, 833-844.	1.8	48
27	Surgery for gastrointestinal metastases of malignant melanoma â€” a retrospective exploratory study. World Journal of Surgical Oncology, 2019, 17, 123.	1.9	8
28	Phase II multicenter open label study of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study). Annals of Oncology, 2019, 30, v907.	1.2	8
29	Real-world data on PD-1 inhibitor therapy in metastatic melanoma. Acta OncolÃ³gica, 2019, 58, 962-966.	1.8	26
30	A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden. Annals of Surgical Oncology, 2019, 26, 2839-2845.	1.5	16
31	Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. BMC Cancer, 2019, 19, 415.	2.6	49
32	HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapyâ€“Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. Cancer Research, 2019, 79, 899-904.	0.9	84
33	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. JAMA Oncology, 2019, 5, 187.	7.1	295
34	Abstract 3185: CAR-T cells can eradicate human uveal melanoma and immune-therapy resistant malignant melanoma in IL-2 transgenic NOD/SCID IL2 receptor gamma knockout mice. , 2019, , .		1
35	Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases. Lancet Oncology, The, 2018, 19, e327.	10.7	22
36	A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma. Cell Death and Disease, 2018, 9, 810.	6.3	38

#	Article	IF	Citations
37	BRAF mutation as a prognostic marker for survival in malignant melanoma: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2018, 36, e21566-e21566.	1.6	8
38	Mouse avatars take off as cancer models. Nature, 2018, 562, 192-192.	27.8	2
39	Hyperbaric oxygen treatment reverses radiation induced pro-fibrotic and oxidative stress responses in a rat model. Free Radical Biology and Medicine, 2017, 103, 248-255.	2.9	33
40	Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nature Communications, 2017, 8, 707.	12.8	123
41	BET bromodomain inhibitors synergize with ATR inhibitors in melanoma. Cell Death and Disease, 2017, 8, e2982-e2982.	6.3	17
42	Adjuvant therapies for malignant melanoma. British Journal of Surgery, 2016, 103, 1095-1096.	0.3	2
43	Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion. Annals of Surgical Oncology, 2016, 23, 1327-1334.	1.5	24
44	Downregulation of tollâ€like receptor 4 and <scp>IL</scp>â€6 following irradiation of the rat urinary bladder. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 698-705.	1.9	19
45	Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts. Oncotarget, 2016, 7, 23801-23811.	1.8	13
46	Abstract 642: Hypoxia-regulated gene expression explains differences between cell line-derived xenografts and patient-derived xenografts. , 2016, , .		0
47	Abstract B38: Melanoma patient-derived xenografts accurately models the disease and develop fast enough to guide treatment decisions. , 2015, , .		0
48	Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nature Genetics, 2014, 46, 1258-1263.	21.4	269
49	Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial. Trials, 2014, 15, 317.	1.6	33
50	Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions. Oncotarget, 2014, 5, 9609-9618.	1.8	62
51	Abstract 1215: Identifying new treatment options for metastatic melanoma using patient derived xenografts: Defining the role of Pim kinases. , 2014, , .		0
52	Bacterial flora of the human oral cavity, and the upper and lower esophagus. Ecological Management and Restoration, 2013, 26, 84-90.	0.4	94
53	Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain. Scandinavian Journal of Gastroenterology, 2013, 48, 274-284.	1.5	71
54	Nitric oxide and endothelin-1 release after one-lung ventilation during thoracoabdominal esophagectomy. Ecological Management and Restoration, 2013, 26, 853-858.	0.4	2

#	Article	IF	Citations
55	The effects of a novel metabotropic glutamate receptor 5 antagonist (<scp>AZD</scp>2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers. Alimentary Pharmacology and Therapeutics, 2012, 35, 1231-1242.	3.7	39
56	Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Alimentary Pharmacology and Therapeutics, 2011, 33, 1113-1122.	3.7	123
57	Risk of clinically relevant bleeding in warfarinâ€treated patientsâ€”influence of SSRI treatment. Pharmacoepidemiology and Drug Safety, 2009, 18, 412-416.	1.9	59
58	A magnetic resonance imaging study of intestinal dilation in Trypanosoma cruzi-infected mice deficient in nitric oxide synthase. American Journal of Tropical Medicine and Hygiene, 2008, 79, 760-7.	1.4	12
59	Reporting of adverse drug reactions may be influenced by feedback to the reporting doctor. European Journal of Clinical Pharmacology, 2007, 63, 505-508.	1.9	18
60	Epithelial barrier integrity and intraluminal nitric oxide production in response to acid perfusion of the ferret oesophagus. Acta Physiologica Scandinavica, 2005, 183, 211-218.	2.2	2
61	Acid Challenge to the Esophageal Mucosa: Effects on Local Nitric Oxide Formation and Its Relation to Epithelial Functions. Digestive Diseases and Sciences, 2005, 50, 640-648.	2.3	12
62	Acid Challenge to the Human Esophageal Mucosa: Effects on Epithelial Architecture in Health and Disease. Digestive Diseases and Sciences, 2005, 50, 1488-1496.	2.3	29
63	Effects of Dietary Nitrate on Oesophageal Motor Function and Gastro-Oesophageal Acid Exposure in Healthy Volunteers and Reflux Patients. Digestion, 2003, 68, 49-56.	2.3	10
64	Impaired relaxation of stomach smooth muscle in mice lacking cyclic GMP-dependent protein kinase I. British Journal of Pharmacology, 2000, 129, 395-401.	5.4	53
65	CHOLINERGIC NERVES IN HUMAN CORPUS CAVERNOSUM AND SPONGIOSUM CONTAIN NITRIC OXIDE SYNTHASE AND HEME OXYGENASE. Journal of Urology, 2000, 164, 868-875.	0.4	95
66	CHOLINERGIC NERVES IN HUMAN CORPUS CAVERNOSUM AND SPONGIOSUM CONTAIN NITRIC OXIDE SYNTHASE AND HEME OXYGENASE. Journal of Urology, 2000, 164, 868-875.	0.4	29
67	The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO Journal, 1999, 18, 37-48.	7.8	304
68	Localization and activity of nitric oxide synthases in the gastrointestinal tract of Trypanosoma cruzi-infected mice. Journal of Neuroimmunology, 1999, 99, 27-35.	2.3	16
69	The nitric oxide pathway in pig isolated calyceal smooth muscle. Neurourology and Urodynamics, 1999, 18, 673-685.	1.5	5
70	Heme oxygenase-1, heme oxygenase-2 and biliverdin reductase in peripheral ganglia from rat, expression and plasticity. Neuroscience, 1999, 95, 821-829.	2.3	21
71	CO-LOCALIZATION OF CARBON MONOXIDE AND NITRIC OXIDE SYNTHESIZING ENZYMES IN THE HUMAN URETHRAL SPHINCTER. Journal of Urology, 1999, 161, 1968-1972.	0.4	46
72	CO-LOCALIZATION OF CARBON MONOXIDE AND NITRIC OXIDE SYNTHESIZING ENZYMES IN THE HUMAN URETHRAL SPHINCTER. Journal of Urology, 1999, , 1968-1972.	0.4	2

#	Article	IF	Citations
73	Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO Journal, 1998, 17, 3045-3051.	7.8	466
74	Mediators and mechanisms of relaxation in rabbit urethral smooth muscle. British Journal of Pharmacology, 1998, 123, 617-624.	5.4	41
75	NITRIC OXIDE SYNTHASE IN THE HETEROGENEOUS POPULATION OF INTRAMURAL STRIATED MUSCLE FIBRES OF THE HUMAN MEMBRANOUS URETHRAL SPHINCTER. Journal of Urology, 1998, 159, 1091-1096.	0.4	54
76	The Nitric Oxide Synthase/ Nitric Oxide and Heme Oxygenase/ Carbon Monoxide Pathways in the Human Ureter. European Urology, 1998, 33, 214-221.	1.9	28
77	Morphological relations between haem oxygenases, NO-synthase and VIP in the canine and feline gastrointestinal tracts. Journal of the Autonomic Nervous System, 1997, 65, 49-56.	1.9	43
78	Pitfalls using metalloporphyrins in carbon monoxide research. Trends in Pharmacological Sciences, 1997, 18, 193-195.	8.7	95
79	Pitfalls using metalloporphyrins in carbon monoxide research. Trends in Pharmacological Sciences, 1997, 18, 193-195.	8.7	129
80	Inhibition of stimulated cyclic AMP production by multiple neuropeptide Y receptors in the rat brainstem. Neuroscience Letters, 1997, 221, 113-116.	2.1	5
81	Î± -Latrotoxin-induced transmitter release in feline oesophageal smooth muscle: focus on nitric oxide and vasoactive intestinal peptide. British Journal of Pharmacology, 1997, 120, 31-38.	5.4	10
82	Carbon monoxideâ€induced relaxation and distribution of haem oxygenase isoenzymes in the pig urethra and lower oesophagogastric junction. British Journal of Pharmacology, 1997, 120, 312-318.	5.4	58
83	Neurotransmitter release evoked by Î±-latrotoxin in the smooth muscle of the female pig urethra. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 356, 151-158.	3.0	12
84	Several neuropeptide Y receptors modulate cyclic AMP production in the rat brainstem. Proceedings of the Western Pharmacology Society, 1997, 40, 21-3.	0.1	0
85	Localization and activity of haem oxygenase and functional effects of carbon monoxide in the feline lower oesophageal sphincter. British Journal of Pharmacology, 1996, 118, 392-399.	5.4	53
86	Modulation of carbon monoxide production and enhanced spatial learning by tin protoporphyrin. NeuroReport, 1995, 6, 1369-1372.	1.2	24
87	Carbon monoxide as a putative messenger molecule in the feline lower oesophageal sphincter of the cat. NeuroReport, 1995, 6, 1389-1393.	1.2	30
88	Nitric oxide pathway in cat esophagus: localization of nitric oxide synthase and functional effects. American Journal of Physiology - Renal Physiology, 1995, 268, G59-G70.	3.4	24
89	Distribution and effects of pituitary adenylate cyclase activating peptide in cat and human lower oesophageal sphincter. British Journal of Pharmacology, 1995, 116, 2873-2880.	5.4	31
90	Factors involved in the relaxation of female pig urethra evoked by electrical field stimulation. British Journal of Pharmacology, 1995, 116, 1599-1604.	5.4	56

#	Article	IF	Citations
91	Inhibition by zinc protoporphyrinâ€IX of receptorâ€mediated relaxation of the rat aorta in a manner distinct from inhibition of haem oxygenase. British Journal of Pharmacology, 1995, 115, 186-190.	5.4	36
92	Nitric oxide synthase-containing, peptide-containing, and acetylcholinesterase-positive nerves in the cat lower oesophagus. The Histochemical Journal, 1994, 26, 721-733.	0.6	47
93	The role of the Lâ€arginine/nitric oxide pathway for relaxation of the human lower oesophageal sphincter. Acta Physiologica Scandinavica, 1993, 149, 451-459.	2.2	49